Crossmark

Benefits of BV-AVD (Brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine) versus ABVD (doxorubicin hydrochloride, bleomycin sulfate, vinblastine sulfate, dacarbazine) in patients with advanced-stage Hodgkin's lymphoma: an analysis of the ECHELON 1 trial by the GATLA group using the Delphi Method

Crossref DOI link: https://doi.org/10.1016/j.htct.2024.07.007

Published Print: 2024-12

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Pavlovsky, Astrid

Altuve, Juan Ignacio Garcia https://orcid.org/0009-0009-9090-8234
Cerutti, Amalia

Fiad, Lorena

Kurgansky, Nicolás

Warley, Fernando https://orcid.org/0000-0002-2589-8190
Negri Aranguren, Florencia
Funding

Funding for this research was provided by:

Takeda Pharmaceuticals USA Inc
License Information

Text and Data Mining valid from 2024-12-01

Text and Data Mining valid from 2024-12-01

Version of Record valid from 2024-09-17
More Information

This article is maintained by: Elsevier

Article Title: Benefits of BV-AVD (Brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine) versus ABVD (doxorubicin hydrochloride, bleomycin sulfate, vinblastine sulfate, dacarbazine) in patients with advanced-stage Hodgkin's lymphoma: an analysis of the ECHELON 1 trial by the GATLA group using the Delphi Method

Journal Title: Hematology, Transfusion and Cell Therapy

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.htct.2024.07.007

Content Type: article

Copyright: © 2024 Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular. Published by Elsevier España, S.L.U.

Document is current

Any future updates will be listed below